Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; Three cases

Simple item page
dc.contributor.buuauthorAkkaya, Cengiz
dc.contributor.buuauthorKaya, Berrin Yalınbaş
dc.contributor.buuauthorKotan, Zenep
dc.contributor.buuauthorSarandol, Aslı
dc.contributor.buuauthorErsoy, Canan
dc.contributor.buuauthorKirli, Selçuk
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı.tr_TR
dc.contributor.researcheridAAH-8861-2021tr_TR
dc.contributor.scopusid14061855100tr_TR
dc.contributor.scopusid57213735495tr_TR
dc.contributor.scopusid15044759000tr_TR
dc.contributor.scopusid14020405100tr_TR
dc.contributor.scopusid6701485882tr_TR
dc.contributor.scopusid14019745700tr_TR
dc.date.accessioned2022-01-11T07:36:05Z
dc.date.available2022-01-11T07:36:05Z
dc.date.issued2009-08
dc.description.abstractSchizophrenia is a chronic and debilitating psychotic mental disorder that affects about 1% of the world's population. Antipsychotic drugs are the mainstay of treatment in schizophrenia. Hyperprolactinemia, which is a common side effect of typical antipsychotics, is also associated with the use of some of the newer atypical agents. Antipsychotics may enhance prolactinoma growth as manifested by an increase in serum prolactin concentration. Prolactin-secreting pituitary adenomas possibly related with antipsychotics have been described in the literature. To our knowledge, this is the first series of cases showing a possible relation between pituitary adenomas and amisulpride treatment in patients with schizophrenia.en_US
dc.identifier.citationAkkaya, C. vd. (2009). "Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; Three cases". Journal of Psychopharmacology, 23(6), 723-726.en_US
dc.identifier.endpage726tr_TR
dc.identifier.issn0269-8811
dc.identifier.issue6tr_TR
dc.identifier.pubmed18562408tr_TR
dc.identifier.scopus2-s2.0-67651151346tr_TR
dc.identifier.startpage723tr_TR
dc.identifier.urihttps://doi.org/10.1177/0269881108091252
dc.identifier.urihttps://journals.sagepub.com/doi/10.1177/0269881108091252
dc.identifier.urihttp://hdl.handle.net/11452/23989
dc.identifier.volume23tr_TR
dc.identifier.wos000268187400017tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherSage Publicationsen_US
dc.relation.journalJournal of Psychopharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAmisulprideen_US
dc.subjectHyperprolactinemiaen_US
dc.subjectPituitary adenomaen_US
dc.subjectSecreting pituitary-adenomaen_US
dc.subjectGrowthen_US
dc.subjectSchizophreniaen_US
dc.subjectThioridazineen_US
dc.subjectNeurolepticsen_US
dc.subjectRisperidoneen_US
dc.subjectMedicationen_US
dc.subjectDisorderen_US
dc.subjectWomanen_US
dc.subjectNeurosciences & neurologyen_US
dc.subjectPharmacology & pharmacyen_US
dc.subjectPsychiatryen_US
dc.subject.emtreeAlprazolamen_US
dc.subject.emtreeAmisulprideen_US
dc.subject.emtreeAripiprazoleen_US
dc.subject.emtreeBiperidenen_US
dc.subject.emtreeFluvoxamineen_US
dc.subject.emtreeHaloperidolen_US
dc.subject.emtreeOlanzapineen_US
dc.subject.emtreeProlactinen_US
dc.subject.emtreeQuetiapineen_US
dc.subject.emtreeRisperidoneen_US
dc.subject.emtreeThioridazineen_US
dc.subject.emtreeValproic aciden_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeCase reporten_US
dc.subject.emtreeDiagnostic and statistical manual of mental disordersen_US
dc.subject.emtreeDrug dose increaseen_US
dc.subject.emtreeDrug dose reductionen_US
dc.subject.emtreeDrug substitutionen_US
dc.subject.emtreeDrug withdrawalen_US
dc.subject.emtreeExtrapyramidal symptomen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHyperprolactinemiaen_US
dc.subject.emtreeHypophysis adenomaen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMicroadenomaen_US
dc.subject.emtreeNuclear magnetic resonanceen_US
dc.subject.emtreeNuclear magnetic resonance imagingen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeProlactin blood levelen_US
dc.subject.emtreeProlactinomaen_US
dc.subject.emtreeSchizophreniaen_US
dc.subject.meshAdulten_US
dc.subject.meshAntipsychotic agentsen_US
dc.subject.meshBrainen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshHyperprolactinemiaen_US
dc.subject.meshMagnetic resonance imagingen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshPituitary neoplasmsen_US
dc.subject.meshProlactinen_US
dc.subject.meshProlactinomaen_US
dc.subject.meshPsychiatric status rating scalesen_US
dc.subject.meshSchizophreniaen_US
dc.subject.meshSchizophrenic psychologyen_US
dc.subject.meshSulpirideen_US
dc.subject.scopusHyperprolactinemia; Prolactin; Aripiprazoleen_US
dc.subject.wosClinical neurologyen_US
dc.subject.wosNeurosciencesen_US
dc.subject.wosPharmacology & pharmacyen_US
dc.subject.wosPsychiatryen_US
dc.titleHyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; Three casesen_US
dc.typeArticle
dc.wos.quartileQ1en_US
dc.wos.quartileQ2en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus